Skip to main content

Treatment Clinical Trials for Non-Small Cell Lung Cancer

Review the non-small cell lung cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 276-300 of 448

Comparison of In-Home versus In-Clinic Administration of Subcutaneous Nivolumab through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Oligoprogressive Non-small Cell Lung Carcinoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Segmentectomy for Treating Patients with Non-Small Cell Lung Cancer Treated with Neoadjuvant Therapy, SAINT Trial
Status: Active
Location: Northwestern University, Chicago, Illinois
Chemotherapy and Cemiplimab with or without Alirocumab before Surgery for the Treatment of Lung Cancer in Patients with Stage IB-IIIA Non-small Cell Lung Cancer
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Cemiplimab and Fianlimab before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer, N-PLANC Trial
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Carboplatin, Paclitaxel, and Ramucirumab for the Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Durvalumab for the Treatment of Patients with Stage IA2-III Non-small Cell Lung Cancer who Have Minimal Residual Disease
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Stereotactic Body Radiation Therapy Planning with Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
Status: Active
Location: Northwestern University, Chicago, Illinois
Circulating Tumor DNA Monitoring for Treatment Response Prediction and Treatment Reduction after Surgery in Patients with Stage IB, II, and IIIB Non-small Cell Lung Cancer, DNA-PREDICT Trial
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Immunotherapy versus Chemoimmunotherapy Guided by Circulating Tumor DNA-Based Molecular Response for the Treatment of Stage IV Non-small Cell Lung Cancer
Status: Active
Location: 2 locations
Responder-derived Fecal Matter Transplant and Pembrolizumab for the Treatment of Relapsed/Refractory PD-L1 Positive Non-small Cell Lung Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Status: Active
Location: University of Kentucky/Markey Cancer Center, Lexington, Kentucky
Volrustomig Priming Regimens Exploratory Phase II Platform Study
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Diclofenac for the Treatment of Patients with Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Dual Immune Strategy (Nivolumab and Ipilimumab) versus Single Checkpoint Blockade (Pembrolizumab) in Combination with Chemotherapy for the Treatment of PD-L1 Negative Stage IV Non-small Cell Lung Cancer, DISCERN Trial
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
GT103 in Combination with Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
Status: Active
Location: 3 locations
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Active
Location: 2 locations
Risk-Adapted, Proteomic-Guided (PROphet CB, and CARG-TT) Systemic Therapy for the Treatment of Previously Untreated Unresectable or Metastatic Non-small Cell Lung Cancer
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Status: Active
Location: University of Kentucky/Markey Cancer Center, Lexington, Kentucky
SX-682 with Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
SAR445877 for the Treatment of Locally Advanced or Metastatic ICI-Refractory Non-Small Cell Lung Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas